secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2022-07-14T23:59:59+00:00
Accession:  0000950170-22-012679
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint Pharmaceuticals appoints Karen Zaderej to Board of Directors
---------------------------------------------------------------------

- Karen Zaderej appointed to Board effective July 11, 2022, expanding board to eight members.
- She will serve on the Audit Committee; receives $45k annual retainer plus $10k for committee service.
- Granted 6,000 RSUs and option for 22,000 shares vesting over three years, exercise price at grant date closing price.
- Zaderej is President/CEO/Chair of AxoGen, bringing 35+ years biopharma and medical device experience.
- Company expects her insight to advance lead pipeline asset EYP-1901 for wet AMD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017022012679/0000950170-22-012679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017022012679/eypt-20220711.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-012679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer